Why Is NOVOCURE LTD (NVCR) Stock Up Today?

NovoCure (NVCR) surged 28.39% to $19.99 on July 24, marking its best one-day performance in over 1.5 years. The rally followed the company’s second-quarter earnings report, which highlighted record revenue and a raised 2026 outlook. The medical device maker reported its strongest performance to date, driven by the global expansion of its Optune Pax device and strong patient adoption of its Tumor Treating Fields therapy.

What Happened

NovoCure reported record second-quarter revenue, with a 16% year-over-year increase. The company raised its 2026 revenue guidance to a range of $710 million to $725 million and outlined a target for adjusted EBITDA of $0 million to $15 million. These updates were accompanied by a $90 million cost-cutting initiative aimed at achieving profitability. The successful launch of Optune Pax in Europe and continued global patient growth contributed to the improved performance. The company also provided a presentation deck in conjunction with its earnings call, outlining its strategic progress and financial targets.

What The Data Shows

Despite the sharp price increase, the stock remains within its 52-week range of $9.82 to $20.55. The intraday session showed limited volume so far, with no significant divergence from the 3-month average. The stock opened at $20.11, slightly above the previous day’s close, and traded in a narrow range before settling at $20.02. The company’s fundamentals remain unprofitable, with a trailing twelve-month net margin of -25.7% and a beta of 0.93. Recent insider transactions include sales by the CEO and two directors, totaling $940K in the last 90 days.

What To Watch

Investors should monitor the company’s progress toward profitability and the continued adoption of Optune Pax. No earnings date is provided in the data, but coverage breadth and guidance updates will remain key indicators for the stock’s near-term direction.